KRYS Krystal Biotech, Inc.

Price Chart

Executive Summary

Citigroup upgraded KRYS from Neutral to Buy on January 6, 2026, raising its price target 56% from $198 to $309, part of a 5-firm cluster action. The firm has a 55% accuracy rate on 4,355 calls and an average return of 4.9%, ranking above average among covering firms. Consensus is overwhelmingly bullish: 16 of 18 analysts rate Buy or Strong Buy, with only 2 Holds and no Sells. The mean target is $318.22, median $310, high $399, low $241 — Citigroup's $309 sits just below the median. Momentum is flat (0 upgrades, 0 downgrades in 30 days), but EPS revisions are mixed: 4 upward vs 2 downward for the current fiscal year, though next-quarter estimates saw 1 up and 3 down. Insider selling is notable — $4.4M in sales over the past month, including $2.6M from Director Daniel Janney — but these are routine sales, not clustered around the upgrade. Institutional buying is strong: Bank of America (+38.3%), Wells Fargo (+60.6%), and a new $70M position from Norges Bank. The upgrade is consensus-aligned from an above-average firm, but the large PT hike and cluster action add weight. Bottom line: bullish signal, but the stock already trades above the new PT, limiting near-term upside.

Impact Score

Consensus & Targets

Consensus is heavily bullish: 7 Strong Buy, 9 Buy, 2 Hold, 0 Sell, 0 Strong Sell across 18 analysts. The direction is overwhelmingly positive, with 89% of analysts at Buy or Strong Buy. Citigroup's upgrade aligns with this consensus, reducing its contrarian value.

Current price: $312.58. Mean target: $318.22 (implied upside +1.8%). Median: $310 (implied downside -0.8%). High: $399 (+27.6%). Low: $241 (-22.9%). Citigroup's $309 PT sits just below the median and below the current price, suggesting limited near-term upside from here. The prior PT of $198 was well below the low end of the range.

Recent Analyst Activity

30-day analyst activity: 0 upgrades, 0 downgrades — flat. EPS revision trend is mixed: for the current fiscal year, 4 revisions up vs 2 down in the last 7 days, with EPS estimates rising from $7.57 to $8.51. However, next-quarter estimates saw 1 up and 3 down, with EPS falling from $1.98 to $2.19. The overall trend is slightly positive for the full year but negative for the near term.

Firm Track Record — Citigroup

Citigroup accuracy: 55% on 4355 calls | avg return: 4.9%

Industry benchmark: mean 51% ± 11%. Top tier: ≥61% (mean + 1σ). Based on 6 firms with ≥5 scored calls.

Citigroup has a 55% accuracy rate on 4,355 total calls with a 4.9% average return, ranking above average among firms covering KRYS. On KRYS specifically, they are 57% accurate (4 of 7) with an 11.7% average return. The best performing firm on KRYS is B of A Securities (100% on 2 calls, 36.3% avg return), followed by Chardan Capital (67% on 9 calls, 15.1% avg return). The worst is Cantor Fitzgerald (50% on 2 calls, -13.4% avg return).

Earnings Estimates

Cross-Platform Signals

Insider selling is notable: $4.4M in sales over the past month, including $2.6M from Director Daniel Janney and $200K from Kathryn Romano. These are routine sales (not clustered around the upgrade) and are weak signals per academic literature. Institutional buying is strong: Bank of America added 38.3% ($47M), Wells Fargo added 60.6% ($7.8M), and Norges Bank opened a new $70M position. No congressional trades. Short interest data not available. The institutional buying converges with the bullish analyst signal, while insider selling is a weak divergence.

Documents Analyzed

Report based on filing metadata.

US Market Status